Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02333474

Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient

Safety Issue and Efficacy of Combining Mix Vaccine and Standard Therapy in the Treatment of Lung Carcinoma Patient

Sponsor: Fuda Cancer Hospital, Guangzhou

Interventions MV mix vaccine standard treatment

Updated 5 times since 2017 Last updated: Sep 8, 2015 Started: Jan 31, 2015 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02333474, this PHASE1/PHASE2 trial focuses on Lung Neoplasms and remains completed. Sponsored by Fuda Cancer Hospital, Guangzhou, it has been updated 5 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China